Recent advancements in personalized management of prostate cancer biochemical recurrence after radical prostatectomy
While conventional risk grouping relying on Gleason score and PSA level and kinetics remain the foundation for BCR management, PSMA-PET/CT, novel biomarkers, and artificial intelligence may enable more personalized treatment strategies.
Authors
- Fabian Falkenbach (ORCID: https://orcid.org/0000-0003-1907-3982)
- Tobias Maurer (ORCID: https://orcid.org/0000-0002-5660-7691)
- Jonas Ekrutt (ORCID: https://orcid.org/0000-0002-2257-3219)
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
- Université de Montréal (CA)
Publication Details
- Journal
- Current Opinion in Urology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1097/mou.0000000000001305
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52